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fibrogenic factor both in vitro and in vivo. Endogenous activa-Endogenous hepatocyte growth factor ameliorates chronic re-
tion of HGF tends to preserve kidney structure and function innal injury by activating matrix degradation pathways.
rats with chronic renal disease by activating matrix degradationBackground. Hepatocyte growth factor (HGF) has been
pathways.shown to promote tubule repair and renal regeneration follow-
ing acute injury; however, whether HGF also modulates the
development and progression of chronic renal diseases that
are characterized by progressive tissue fibrosis is uncertain. To The hallmark of chronic kidney diseases progressingexamine this question, this study investigated the functional
to end-stage renal failure is the relentless accumulationconsequence of blocking endogenous HGF signaling in vivo
of extracellular matrix (ECM), which leads to wide-in a model of chronic renal disease. The effects of HGF on
the processes of matrix synthesis and degradation in cultured spread glomerular sclerosis and interstitial fibrosis [1].
renal epithelial cells were also examined. In fact, ECM is constantly synthesized and degraded,
Methods. The level of activity of the HGF/c-met axis was and accumulation of ECM in pathological settings isexamined in rats following 5/6 nephrectomy at multiple time
believed to result from an imbalance in these processes.points. To determine the effects of HGF in modulating chronic
Among the many factors that regulate matrix turnover,renal injury, HGF action was blocked in remnant kidney rats
using an anti-HGF antibody. The effects of HGF on extracellu- a growing body of evidence suggests that peptide growth
lar matrix (ECM) synthesis and degradation were examined factors may be of major importance in maintaining this
in renal epithelial cells by 35S-methionine labeling, Western delicate balance [2–5]. A potential role for hepatocyteblotting, and zymographic analysis.
growth factor (HGF) in regulating these processes wasResults. An increase in renal and systemic production of
recently suggested by the observation that injections ofHGF coupled with an increase in renal c-met was observed in
rats with remnant kidneys. When HGF action was blocked by exogenous HGF prevent renal dysfunction and tubulo-
the administration of an anti-HGF antibody, rats experienced interstitial fibrosis in a murine, genetic model of chronic
a rapid decrease in glomerular filtration rate and increased
renal disease [6]. These data are also consistent withrenal fibrosis. Kidney sections from the antibody-treated rats
studies in liver and lung demonstrating potent antifibro-displayed a marked increase in ECM accumulation and in
a-smooth muscle actin-positive cells in both the interstitium genic effects of HGF [7, 8]. However, the precise role
and tubular epithelium. In vitro studies revealed that HGF of HGF in chronic renal injury, as well as the molecular
reduced net ECM accumulation by human proximal tubule mechanisms underlying HGF’s effects on ECM turnover,
cells (HKC), and this effect was abolished by incubating cells
has not been determined.with an anti-HGF antibody. HGF did not alter the ECM syn-
Extracellular matrix homeostasis depends on the coor-thetic rate in HKC cells. Rather, it markedly increased colla-
genase such as matrix metalloproteinase-9 (MMP-9) protein dinated balance between deposition and removal of
expression, as evidenced by Western blotting and zymographic ECM components. Under normal physiological condi-
analysis. HGF also decreased the expression of tissue inhibitors tions, the modulation of ECM turnover is necessary forof matrix metalloproteinase-1 (TIMP-1) and TIMP-2, the en-
the processes of matrix remodeling and tissue-specificdogenous inhibitors of MMPs.
differentiation to proceed during embryonic develop-Conclusion. These results suggest that HGF is a potent anti-
ment, tissue repair, wound healing, and angiogenesis.
On the other hand, an imbalance in the rates of ECMKey words: remnant kidney, matrix metalloproteinases, tissue inhibi-
production and degradation has been implicated in ators, myofibroblast, antifibrosis factor, progressive tissue fibrosis, epi-
thelial cells. wide range of pathological conditions, including inflam-
mation, tumor invasion, and metastasis. In diseases thatReceived for publication March 2, 1999
are characterized by excess deposition of ECM, accumu-and in revised form May 17, 2000
Accepted for publication June 5, 2000 lation of matrix can result from increased matrix synthe-
sis, decreased matrix removal, or both [9]. ECM degrada-Ó 2000 by the International Society of Nephrology
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tion is tightly controlled by a family of zinc- and calcium- Protein excretion and blood pressure measurements
dependent matrix-degrading enzymes known as matrix Rats were placed in metabolic cages, and urine was
metalloproteinases (MMPs) and their endogenous an- collected for 24 hours. The protein concentration was
tagonists, the tissue inhibitors of MMPs (TIMPs) [9–11]. measured by precipitation with 3% sulfosalicylic acid,
To investigate the actions of HGF in chronic renal and turbidity was determined by measuring absorbance
disease, we first examined the changes in the activity of at 595 nm with a spectrophotometer (Spectronic 501;
the HGF/c-met axis in the remnant kidney model of Milton Roy, Rochester, NY, USA). Awake SBP was
chronic renal disease. We found that HGF/c-met was measured using a photoelectric tail-cuff device (Model
markedly activated in this model and, furthermore, that 29; IITC Inc., Woodland Hills, CA, USA) attached to a
specific blocking HGF signaling promoted renal injury. recorder (Model SE 120; IITC Inc.). For each rat, the
Since the balance between the activities of MMPs and value recorded represented the mean of four to six mea-
TIMPs appears to be a key determinant of the overall surements obtained at a single sitting.
ECM homeostasis, we then examined the effects of HGF
Functional studieson these substances in cultured renal tubular cells. Our
data suggest that HGF is a potent antifibrogenic factor Three weeks after ablation and after one week of
that activates matrix degradation networks both in vitro injections with either preimmune serum or anti-HGF
and in vivo by increasing in MMP expression and de- antibody, rats were anesthetized with thiobutabarbital
creasing in TIMPs production. (100 mg/kg, IP). A polyethylene catheter (PE50) was
inserted into the femoral artery and mean arterial pres-
sure (AP) was measured by a pressure transducer con-METHODS
nected to a computer running WINDAS software. A
Design of the animal studies tracheostomy was performed, and polyethelene cathe-
All studies were performed in male Sprague-Dawley ters were inserted into both jugular veins and the left
rats with initial weights of 180 to 250 g. For creation of ureter for infusion of solutions and collection of urine.
the remnant kidney model, rats were fasted overnight, All rats received isooncotic rat plasma at a rate of 0.1
anesthetized with pentobarbital [50 mg/kg, intraperito- mL/min for a total of 10 mL/kg body weight, followed
neally (IP)], and subjected to right nephrectomy and by a sustained infusion of plasma at a rate of 0.5 mL/hour
segmental infarction of approximately 2/3 of the left kid- to compensate for surgical losses and specimen collec-
ney by ligation of two to three branches of the left main tion. The rats also received a 0.5 mL intravenous bolus
renal artery as previously described [12, 13]. For studies of [3H] inulin in normal saline followed by an infusion at
of HGF and c-met gene expression, rats were sacrificed 0.5 mL/hour. After an equilibration period of 45 minutes,
at multiple time points following renal ablation. The two timed urine collections of 15 minutes each were
kidneys were snap frozen in liquid nitrogen and stored made. At the midpoint of each collection, a 100 mL sample
at 2808C pending further analysis. of blood was collected in microhematocrit tubes. Inulin
To examine the effects of HGF in modulating chronic concentration in serum and urine was determined by
renal injury, HGF activity was blocked in vivo using an scintillation counting (Beckman model LS6500). Inulin
anti-HGF antibody. The specificity, titer, and neutraliz- clearance was determined by the standard formula. Of
ing ability of the antiserum were fully characterized as note, two animals in the anti-HGF antibody group were
described previously (discussed later in this article) [14]. too ill to tolerate anesthesia and surgery and, therefore,
Rats underwent subtotal nephrectomy as described pre- the accurate determination of glomerular filtration rate
viously in this article. To ensure that a similar degree of (GFR) by inulin clearance. In these rats, GFR was esti-
renal mass reduction was produced in all rats, serum mated from the clearance of creatinine obtained using
creatinine was measured after three days, and only rats creatinine concentrations measured in urine collected
with values between 0.8 and 1.2 mg/dL were used. Rats over 24 hours on the day prior to sacrifice and plasma
were housed in standard cages and allowed free access to obtained at the time of sacrifice.
food and water. All rats were fed standard chow (Purina
Morphologic and immunohistochemical studiesMills, Richmond, IN, USA) for the duration of the study.
Body weight, awake systolic blood pressure (SBP), and At the conclusion of the clearance study, the kidney
urinary protein excretion were monitored. After two was fixed in situ by perfusion for five minutes at the
weeks, rats were randomly assigned to receive daily in- measured blood pressure with 10% formalin. The kidney
travenous injections of either control, preimmune serum, was excised and weighed. Two coronal sections of tissue
or a specific high titer anti-HGF antibody via a tail vein were embedded in paraffin for light microscopy. Sections
for seven days, after which functional and morphologic 3 mm thick were stained with hematoxylin and eosin.
Morphologic evidence of injury was scored for each ratstudies were performed.
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by one observer who was blinded as to the group. The times with phosphate-buffered saline (PBS) containing
total number of glomeruli present on each slide were 0.05% Tween 20, a 100 mL aliquot of an enzyme-linked
counted and assessed for each rat (range 42 to 142). polyclonal antibody specific for rat HGF was added, and
The incidence of glomerular sclerosis, tubular dilation/ the plates were incubated for another two hours. They
hyaline deposition, and interstitial fibrosis was quantita- were then washed four times before enzyme substrate
tively assessed. Glomerular sclerosis was graded based was added. The plates were allowed to stand for 30 min-
on the number of glomerular quarters that were affected utes, and the reaction was stopped by the addition of
divided by the total number of glomeruli for a given 50 mL of 1 N H2SO4. Absorbance was read with a Bio-
slide. Tubulointerstitial changes were graded on a 0 to Tek EL340 automated microplate reader (Winooski,
3 scale. A composite injury score was then generated VT, USA).
from the sum of the glomerular sclerosis, tubular dila-
Determination of tissue HGF and c-met mRNA levelstion/hyaline deposition, and interstitial fibrosis scores.
The extent of collagen deposition was further quanti- Total RNA was isolated from kidney tissues after ho-
tated using another set of sections stained with Masson- mogenization in RNAzol solution (Cinna/Biotecx, Friends-
Trichrome, which labels interstitial collagen a blue color wood, TX, USA) according to the instructions specified
[15]. To quantitate and localize the a-smooth muscle by the manufacturer. RNA was quantitated by ultraviolet
actin (a-SMA)-positive cells in the kidney, tissue sections absorbance measurements at 260 nm, its purity docu-
were evaluated immunohistochemically by staining with mented by comparison of ultraviolet absorbance read-
a monoclonal anti-a-SMA antibody (Sigma, St. Louis, ings at 260 and 280 nm, and its integrity assured by
MO, USA) using the avidin-biotin immunoperoxidase demonstration of intact ribosomal RNA bands on ethid-
method (Vectastain ABC kit; Vector Laboratories, Burl- ium bromide-stained agarose gels. Northern blotting was
ingame, CA, USA). To measure the abundance a-SMA performed on RNAs as previously described in our labo-
protein in kidney, frozen tissues were homogenized and ratory [16]. Samples of 20 mg total RNA were electropho-
subjected to Western blotting using the anti-a-SMA anti- resed on 1.0% formaldehyde-agarose gels and then
body (discussed later in this article). transferred to Genescreen plus filters (DuPont, Boston,
MA, USA) by capillary blot. Filters were prehybridizedProduction of a high titer anti-HGF antibody
for four hours at 658C in a buffer containing 5 3 standard
A high-titer, specific anti-HGF polyclonal antibody saline citrate (SSC), 5 3 Denhardt’s solution, 0.1% so-
was produced by a commercial vendor (Animal Pharm dium dodecyl sulfate (SDS), and 100 mg/mL denatured
Services, Inc., Healdsburg, CA, USA) using a standard
salmon sperm DNA. 32P-labeled DNA probes were pre-
protocol. A New Zealand rabbit was immunized with
pared by the random primer labeling kit (Stratagene, Lapurified recombinant HGF (generous gift of Genentech,
Jolla, CA, USA) using [a-32P]dCTP. Denatured probesInc., South San Francisco, CA, USA) and Freund’s com-
were added to the hybridization buffer at a concentrationplete adjutant. At four weeks later and every week there-
of 1 to approximately 2 3 106 cpm/mL. Filters were washedafter, the rabbit received a boost injection of HGF with
twice in 2 3 SSC/0.5% SDS at room temperature for 10Freund’s incomplete adjuvant. Beginning six weeks after
minutes, followed by two washes in 0.1 3 SSC/0.5% SDSthe initial injection, blood was collected from the animal
at 658C for 20 minutes. The filters were then exposed toone time per week, and the serum was separated, yielding
Kodak XAR x-ray film (Eastman Kodak, Rochester, NY,400 mL of antiserum. The specificity and titer of the
USA) at 2808C.antiserum were characterized by enzyme-linked immu-
noabsorbant assay (ELISA), Western blot, immunocyto- Cell culture and treatment
chemistry, respectively, and its neutralizing ability was
Human renal proximal tubular epithelial cells (HKC-8)confirmed by blocking HGF’s actions on renal tubular
were kindly provided by Dr. L. Racusen of Johns Hop-epithelial cells in vitro as described previously [14].
kins University (Baltimore, MD, USA) [17]. Cells were
Determination of HGF protein levels in plasma cultured in Dulbecco’s modified Eagle’s medium
(DMEM)-F12 supplemented with 5% fetal bovine serumThe amount of HGF in rat plasma was determined
(FBS; Life Technologies, Inc., Grand Island, NY, USA).using a commercial enzyme immunoassay (EIA) kit spe-
For HGF treatment, HKC cells were seeded at approxi-cific for rat HGF purchased from the Institute of Immu-
mately 60% confluency in the complete medium con-nology (Tokyo, Japan). The kit uses a sandwich method
taining 5% FBS. Twenty-four hours later, the cells wereconsisting of three steps. Briefly, a monoclonal antibody
changed to serum-free medium, and recombinant humanspecific for rat HGF was coated onto 96-well microtiter
HGF was added at the final concentration of 20 ng/mL.plates. Fifty microliter aliquots of standard rat HGF or
The cells and conditioned media were collected at differ-samples of plasma were added to the wells and incubated
for 18 hours at room temperature. After washing four ent time points for further characterization.
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Establishment of an HGF-producing renal epithelial For measurement of ECM synthetic rate, cells were
pulsed with 50 mCi/mL of Trans-[35S] for 1.5 hours atcell line
378C. The incorporation rate of 35S into ECM substrateHepatocyte growth factor-producing renal epithelial
was counted as described previously in this article.cells were established by stable transfection of HKC cells
using the human HGF expression plasmid pCMV-HGF
Gelatin zymographic analysis
constructed by cloning a full-length human HGF cDNA
Zymographic analysis of MMPs in the supernatant ofinto the eukaryotic expression vector pcDNA3 (Invitro-
cultured renal epithelial cells was carried out essentiallygen, San Diego, CA, USA), as described previously
according to the method described by Kitamura et al [20].[14, 18]. Briefly, the HKC cells were transfected with
Briefly, an equal number of the HKC and H4 cells were5 mg/well of the pCMV-HGF expression plasmid using
seeded on six-well plates at a density of 4 3 105/well inthe DNA-calcium phosphate coprecipitation method ac-
DMEM-F12 medium containing 5% FBS. Twenty-fourcording to the instructions provided for the CellPhect
hours later, culture medium was changed to 0.7 mL oftransfection kit (Pharmacia, Uppsala, Sweden) [14, 19].
medium containing 0.5% FBS, and the incubation con-The transfected cells were cultured in selective medium
tinued for two days. The conditioned medium was col-containing G418 (Geneticin; Life Technologies, Inc.) at
lected and centrifuged at 13,000 3 g for five minutes toa final concentration of 800 mg/mL. Neomycin-resistant
remove any cell debris. The protein concentration wasclones were individually transferred into six-well plates
determined using a protein assay kit with bovine serumfor expansion using a cloning cylinder (Sigma Chemical).
albumin as a standard (Sigma Chemical). A constantAfter two further passages in selective medium, expanded
amount of protein (15 mg) from the conditioned mediumindependent clones were cultured in standard medium. As
was loaded into 7.5% SDS-polyacrylamide gel con-a mock-transfection control, the pcDNA3 vector plasmid
taining 1 mg/mL gelatin type A from porcine skin (Sigmawithout HGF cDNA was used to transfect HKC cells in
Chemical). After electrophoresis, SDS was removeda manner identical to the pCMV-HGF plasmid.
from the gel by incubation in 2.5% Triton X-100 at roomThe amount of human HGF in the conditioned media
temperature for 30 minutes with gentle shaking. The gelof HKC cells and HGF-transfected cells was measured
was washed well with distilled water to remove detergentusing a commercial ELISA kit purchased from R&D
and incubated at 378C overnight in a developing bufferSystems (Minneapolis, MN, USA), as described pre-
containing 50 mmol/L Tris-HCl, pH 7.6, 0.2 mol/L NaCl,viously [14]. This ELISA is able to detect 0.1 ng/mL of
5 mmol/L CaCl2, and 0.02% Brij 35. The gel was thenpurified HGF and displays no cross-reactivity with a wide
stained with a solution of 30% methanol, 10% glacialvariety of other cytokines.
acetic acid, and 0.5% Coomassie blue G250, followed by
ECM accumulation assay: Trans-[35S] incorporation destaining in the same solution without dye. Proteinase
activity was detected as unstained bands on a blue back-Equal numbers of the HKC and HGF-transfected H4
ground representing areas of gelatin digestion.cells were seeded on 12-well plates at a high density (4 3
105/well) in DMEM-F12 medium containing 5% FBS.
Western immunoblot analysisThe cells were grown to confluence following a 24-hour
Human proximal tubule cells and HGF-transfectedincubation, and culture medium was changed to a ser-
H4 cells were solubilized with RIPA lysis buffer (1%um-, methionine-, and cysteine-free RPMI-1640 medium
NP40, 0.1% SDS, 100 mg/mL phenylmethylsulfonyl(Life Technologies, Inc.). Trans-[35S]-labeled methionine
fluoride (PMSF), 0.5% sodium deoxycholate, 1 mmol/L(ICN Pharmaceuticals, Irvine, CA, USA) was added
sodium orthovanadate, 2 mg/mL aprotin, 2 mg/mL leu-to the culture medium at a final concentration of 50
peptin in PBS) at 48C for 20 minutes, and the superna-mCi/mL, and the cells were allowed to incubate for vari-
tants of the cells (conditioned medium) were collectedous time periods as indicated. Culture medium was re-
after centrifugation at 13,000 g at 48C for five minutes,moved, and the cells were washed twice with cold PBS.
as described previously [21]. Protein concentration wasThe cells were detached from the plates by adding 1 mL
determined using a protein assay kit (Sigma Chemical),of 0.25 mol/L NH4OH per well and incubating for 30
and cell lysates were mixed with an equal amount 2 3minutes at 378C. The ECM substrate remaining in the
loading buffer (100 mmol/L Tris-HCl, 4% SDS, 20%culture plates was washed with distilled H2O and 70%
glycerol, and 0.2% bromophenol blue). Samples wereethanol and precipitated with ice-cold 5% trichloroacetic
separated on an 10 or 15% SDS-polyacrylamide gelacid (TCA) for 10 minutes, respectively. The ECM was
under nonreducing condition. The proteins were elec-then solubilized with 1 mL of solution containing 2.5%
trotransferred to a polyvinylidene difluoride (PVDF)SDS/10% glycerol/50 mmol/L Tris-HCl, pH 6.8, for 30
membrane (Amersham, Arlington Heights, IL, USA)minutes at 378C. One milliliter samples were suspended
in transfer buffer containing 48 mmol/L Tris-HCl, 39in 6 mL scintillation fluid and counted in a Beckman
LS6500 multipurpose scintillation counter. mmol/L glycine, 0.037% SDS, and 20% methanol at 48C
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for two hours. Nonspecific binding to the membrane was
blocked for one hour at room temperature with 5% Car-
nation nonfat milk in TBS buffer (20 mmol/L Tris-HCl,
150 mmol/L NaCl, and 0.1% Tween 20), and then the
membrane was incubated for 18 hours at 48C with various
antihuman MMPs or TIMPs antibodies, respectively (On-
cogene Research Products, Cambridge, MA, USA). Bind-
ing of primary antibodies was followed by incubation
for one hour at room temperature with the secondary
goat anti-mouse IgG horseradish peroxidase conjugate
in 1% nonfat milk. The signals were visualized by the en-
hanced chemiluminescence system (ECL; Amersham).
Western blot was also employed to determine the
aSMA abundance in kidney tissue of remnant kidney
rats in which HGF action was blocked by administration
of a high-titer, anti-HGF serum as described previously
in this article. Kidney tissue derived from either pre-
immune serum group or anti-HGF group was homoge-
nized in RIPA buffer as described previously [19]. The
tissue lysate was subjected to Western immunoblotting
with anti-aSMA (Sigma Chemical). The same blot was
stripped and reprobed with specific antibody against ac-
tin (Santa Cruz Biochemicals, Santa Cruz, CA, USA).
Determination of TIMP-1 levels by ELISA
The amount of TIMP-1 in the conditioned media of
HKC cells and HGF-transfected cells was measured us-
ing the Biotrak human TIMP-1 ELISA kit according to
the manufacturer’s instructions (Amersham, Minneapo-
lis, MN, USA). This assay measures total TIMP-1 abun-
dance, which includes free TIMP-1 and TIMP-1/MMP
binding complex.
Statistical analysis
Fig. 1. Hepatocyte growth factor (HGF) and c-met mRNA levels inAnimals were randomly assigned to control and treat- the kidneys of sham and remnant rats at multiple time points after
ment groups. All data are expressed as mean 6 SE. renal mass reduction. (A) Representative Northern analysis results. The
kidney tissue total RNA was probed with cDNA probes for rat HGFMorphologic evidence of injury was scored for each ani-
and rat c-met, respectively. The same blot was stripped and hybridized
mal by one observer who was blinded as to the treatment with the probe for 18S RNA to ensure equal loading. (B) Results of
scanning densitometry showing mRNA abundance relative to baselinegroups. For Western blot analysis, quantitation was per-
(fold induction). Data are average of four animals per time point.formed by scanning and determination of the intensity A biphasic induction of HGF (d) and c-met (s) gene expression is
of the hybridization signals using Quantity One analysis demonstrated.
software. Statistical analysis of the data was performed
by Student’s t-test using SigmaStat software (Jandel Sci-
entific, San Rafael CA, USA). A P value of less than As shown in Figure 1, a biphasic induction of both HGF
0.05 was considered statistically significant. and c-met was observed. An early 13-fold increase in
the HGF mRNA level was observed peaking at 6 hours
after ablation and returning to baseline within 48 hoursRESULTS
after ablation. A parallel, although slightly delayed, nine-
Activation of HGF and c-met axis in remnant fold increase in c-met gene expression peaked 24 hours
kidney rats after ablation. The lag in the c-met peak is consistent
Hepatocyte growth factor and c-met mRNA levels with our observation in vitro that HGF itself induces
were determined by Northern analysis in the kidneys of c-met gene expression [14, 21]. This early increase in
HGF/c-met activity corresponds to the initial hyperplas-remnant rats at multiple time points following surgery.
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HGF protein to below that observed in sham-operated
rats. Of note, the mechanism by which the anti-HGF
antibody decreased circulating HGF in remnant rats
treated is not entirely clear. One possibility is that
blocking HGF activity with the anti-HGF inhibited HGF
production, since exogenous HGF up-regulates endoge-
nous HGF production in vivo [7]. The functional conse-
quence following blocking HGF in rats with remnant
kidneys is summarized in Table 1.
Values for serum creatinine were determined three
days after ablation and again at three weeks, after admin-
istration for one week of either the anti-HGF antibody
or preimmune serum. No difference in serum creatinine
between the two groups was observed at three-days post-
nephrectomy, indicating that the degree of renal mass
reduction was similar in the two groups. Creatinine wasFig. 2. Plasma levels of HGF protein in rats. Plasma was collected at
three weeks after ablation from sham-operated, remnant given preim- unchanged in rats that received preimmune serum at
mune serum, or remnant given anti-HGF serum rats. HGF levels were three weeks, suggesting that the GFR remains relativelydetermined using an EIA kit specific for rat HGF. Data are mean 6
constant over this time period, which is consistent withSE of four animals per group. *P , 0.05 vs. either sham or anti-
HGF antibody group. The administration of anti-HGF antibody reduces previous reports of the natural history of renal disease
circulating HGF to baseline levels (sham). in this model. In contrast, approximately a 50% increase
in serum creatinine was observed in rats that received
the anti-HGF antibody, indicative of a marked decline
in GFR in this group. This decline in renal function wastic response that follows reduction in renal mass. HGF
confirmed by clearance studies. Shown in Table 1, afterand c-met levels returned to baseline within one week;
one week of antibody administration, GFR was mark-however, a second increase in mRNA levels was ob-
edly reduced by 55% in rats given the anti-HGF antibodyserved beginning at 14-days postablation. This second
as compared with control. Consistent with the presencerise in HGF/c-met levels corresponds to the time when
of glomerular injury even prior to antibody administra-blood pressure and proteinuria are rising in this model
tion, abnormal protein excretion of similar magnitudeand when morphologic evidence of injury is becoming
was observed at two weeks in both the control and anti-evident [13]. In other studies (data not shown), we have
HGF antibody groups (Table 1). Despite a significantobserved that this late increase in gene expression is
decline in GFR, the protein excretion rate was not in-sustained out to at least eight weeks, the latest time point
creased by anti-HGF antibody administration and re-
we have examined.
mained relatively constant between weeks two and three
To determine whether circulating HGF levels were in both groups. However, the fact that GFR declined
also increased, we measured plasma HGF protein levels by more than 50% in anti-HGF antibody-treated rats
using a commercially available specific EIA for rat HGF. suggests that protein excretion per nephron actually dou-
Shown in Figure 2, a 43% increase in plasma HGF levels bled in that group, consistent with a significant worsening
was observed in remnant rats at three weeks after abla- of glomerular barrier function. Of note, there were no
tion. The magnitude of this increase in plasma HGF significant differences in systemic blood pressure be-
levels in remnant rats is comparable to reported values tween the groups at any time point (data not shown).
for circulating HGF levels in patients with chronic renal
disease [22]. Blocking of HGF signaling in vivo promotes renal
tissue fibrosis
Blocking of HGF signaling in vivo promotes As described previously [13] and illustrated in Figures
renal dysfunction 3 and 4, remnant kidney rats develop glomerular enlarge-
To examine the biologic actions of endogenous HGF ment, mesangial expansion, focal and global glomerular
in chronic renal disease, we blocked HGF activity by sclerosis as well as tubulointerstitial changes, including
injecting a polyclonal anti-HGF antibody. We have pre- tubular dilation, cast formation, and interstitial inflam-
viously demonstrated that this high-titer antibody blocks mation and fibrosis. In general, similar types of glomeru-
many actions of HGF on renal epithelial cells in vitro lar and tubulointerstitial lesions were observed in both
[14]. Also shown in Figure 2, administration of the anti- groups of rats; however, as shown in Figures 3 and 4,
HGF antibody prevented the increase in circulating the magnitude of injury was significantly greater in rats
that received anti-HGF antibody as compared with thoseHGF protein levels in the remnant rats, in fact reducing
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Table 1. Whole animal data
Group parameter Day 3 Week 2 Week 3
Remnant1pre-immune serum (N56)
Serum creatinine mg/dL 0.9760.06 1.0660.05
GFR mL/min 0.7560.18
Protein excretion mg/24 hours 67.2615.8 84.7624.9
Remnant1anti-HGF antibody (N58)
Serum creatinine mg/dL 0.9360.14 1.5360.15a
GFR mL/min 0.3360.09a
Protein excretion mg/24 hours 93.0618.7 85.4617.1
N is the number of animals.
aP , 0.05 vs. pre-immune serum
given preimmune serum. Glomerular and tubulointersti- HGF reduces the net ECM accumulation by renal
epithelial cellstial abnormalities increased concordantly in the anti-
HGF group. In Masson-Trichrome–stained kidney sec- The finding that blocking HGF action augmented re-
tions, interstitial expansion and massive accumulation of nal fibrosis in remnant kidney rats prompted us to exam-
extracellular collagen was evident in the anti-HGF– ine the effects of HGF on ECM turnover in kidney cells
treated group (Fig. 4). Glomerular injury, including mes- in vitro. To investigate the integrated effect of HGF on
angial expansion, focal and global glomerular sclerosis ECM synthesis and degradation, we first examined ECM
with matrix accumulation, was also increased in rats that accumulation by the renal proximal tubular epithelial
received the anti-HGF antibody as compared with those cell (HKC) in which the c-met receptor is abundantly
given preimmune serum. These results suggest that block- expressed using 35S-methinone labeling. This assay mea-
ing endogenous HGF signaling augmented glomerular sures the total net amount of ECM accumulated on a
and interstitial fibrosis in remnant kidney rats. culture dish at a given time point, which depends on the
balance between matrix synthesis and degradation. As
Endogenous HGF signaling is essential for preserving shown in Figure 7A, incubation of HKC cells with exoge-
renal epithelial cell phenotype nous HGF for 24 hours significantly reduced net ECM
We also investigated the effect of blocking HGF sig- accumulation (Fig. 7A). The HGF-induced reduction in
naling on the activation of myofibroblast cells in remnant ECM accumulation was completely abolished by coincu-
kidneys by examining the distribution of a-SMA-positive bation with a specific anti-HGF neutralizing antibody
cells. As shown in Figures 5 and 6, a marked increase but not with preimmune serum (Fig. 7B), demonstrating
in a-SMA expression was found in the kidneys of rats that matrix accumulation is specifically inhibited by
that received anti-HGF antibody as compared with those HGF. Thus, exogenous HGF can decrease net ECM
given preimmune serum. Immunohistochemical localiza- accumulation by human renal epithelial cells in vitro.
tion of a-SMA-positive cells revealed that a-SMA stain- Extracellular matrix accumulation in disease states in
ing was typically limited to small arteries and arterioles vivo is often a gradual process, progressing over months
and occasional interstitial cells in kidneys of rats given to years, and therefore might not be adequately modeled
preimmune serum (Fig. 5A, B). However, a large increase by acute exposure of cultured cells to HGF. To examine
in a-SMA staining was observed in glomeruli and in the long-term actions of HGF on matrix dynamics, we
the interstitium of kidneys from rats in which HGF was established a human renal epithelial cell line (H4) in
blocked (Fig. 5C, D). Of great interest, a significant num- which HGF is constitutively and tonically expressed by
ber of renal tubular epithelial cells stained positively for stably transfecting HKC cells with an HGF expression
plasmid vector. This system provides an in vitro modela-SMA in anti-HGF antibody-treated rats (Fig. 5E, F).
In some sections, a-SMA-positive renal tubular epithe- of the microenvironment of renal epithelial cells in vivo
in kidneys in which the HGF/c-met system is chronicallylial cells appeared to be in the process of detaching from
the epithelium and migrating into interstitium (Fig. 5F). activated, as occurs in the remnant kidney (Figs. 1 and 2)
and other models of chronic renal disease [22]. HGF-This finding is consistent with the hypothesis that in
chronic renal disease, some renal epithelial cells transdif- transfected (H4) cells expressed the 2.3 kb HGF mRNA
transgene and secreted human HGF into the cultureferentiate into a myofibroblastic phenotype, as marked
by the expression of a-SMA [23–25]. Our findings further medium (Fig. 8A, B). In contrast, neither HGF mRNA
nor HGF protein was detected in the parental HKC cellssuggest that endogenous HGF signaling tends to block
this transdifferentiation and to preserve the normal renal or in the cells that were mock transfected. A comparison
of net ECM accumulation and deposition by controlepithelial cell phenotype.
Fig. 3. Representative light micrographs of remnant kidney tissue from
rats given either preimmune serum or anti-HGF antibody. (A) The
control kidney from the rat given preimmune serum shows typical,
mild changes observed in rats three weeks after ablation. Segmental
glomerular sclerosis involving a minority of glomeruli is present. Tu-
bules are normal in appearance and closely spaced. The interstitium is
also within normal limits. (B) An end-stage kidney from an anti-HGF
antibody treated rat with global glomerular sclerosis, tubular dilation,
cast formation, and increased interstitial matrix material (PAS 3200).
(C) Average composite injury scores (see text for details) from remnant
kidney rats given preimmune serum (h) or anti-HGF antibody ( ).
On average, the injury score was significantly increased in rats in which
HGF action was blocked.
Fig. 4. Representative light micrographs demonstrating collagen accumulation in the remnant kidney tissue from rats given either preimmune
serum or anti-HGF antibody. The remnant kidney tissues from rats given either preimmune serum or anti-HGF antibody were sectioned and
stained using the Masson-Trichrome technique to demonstrate interstitial collagen accumulation. (A and B) Control kidney tissue from a rat given
preimmune serum shows mild changes typically observed in rats three weeks after ablation. Glomeruli and tubules are relatively normal in
appearance and are closely spaced. The interstitium is also normal. (C and D) Kidney tissue from an anti-HGF antibody-treated rat shows interstitial
expansion and increased matrix accumulation demonstrated by blue staining (arrow head) and segmental glomerular sclerosis (arrow). (A and C
3200; B and D 3400).
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Fig. 5. Immunohistochemical localization of a-SMA-positive cells in the remnant kidney tissues from rats given either preimmune serum or anti-
HGF antibody. (A and B) Control kidney from a rat given preimmune serum shows a-SMA-positive cells largely limited to blood vessels. Mild
staining in the interstitium is also noted. (C–F ) Kidney tissue from an anti-HGF antibody-treated rat shows a dramatic increase in a-SMA-positive
cells in the renal interstitium, tubules, and glomeruli (C and D). A significant percentage of renal tubular epithelial cells were found to be a-SMA
positive (E and F ). Some of these a-SMA-positive tubular epithelial cells appeared to migrate into interstitium (arrows in F ). (A and C 3200; B
and D–F 3400).
HKC cells and HGF-producing H4 cells revealed that on these data, HGF-producing H4 and control HKC cells
were utilized in subsequent in vitro experiments.constitutive expression of HGF markedly reduced net
ECM accumulation (Fig. 8C). As expected, incubating
Reduction in ECM accumulation by HGF is notthe H4 cells with neutralizing anti-HGF antiserum abol-
mediated by decreasing matrix synthesisished the antifibrogenic action of HGF (Fig. 8D). Of
note, the magnitude of inhibition of the ECM accumula- The reduction of the net ECM accumulation by HGF
tion in HGF-producing H4 cells was greater than in nor- that we observed in renal epithelial cells (Figs. 7 and 8)
mal HKC cells that were acutely treated with HGF, even could result from either a decrease in matrix synthesis
though the concentration of HGF in the conditioned and/or an increase in matrix degradation. To examine
this question, we incubated renal epithelial cells in freshmedia of H4 cells was relatively low (~2.0 ng/mL). Based
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Fig. 6. Specific blocking of HGF signaling in vivo by a neutralizing
antibody increases renal a-SMA expression. SD rats were subjected to
5/6 nephrectomy. Two weeks later, the rats were given daily injections
of either the anti-HGF serum (a-HGF) or preimmune serum for seven
days. Kidney tissue were collected and lyzed for Western blotting with
an anti-a-SMA antibody. Each lane (1 through 6) in the picture repre-
sents an individual rat. The same sample was reprobed with an anti-
actin antibody.
serum-free medium containing 35S-methionine for 1.5
hours. We reasoned that protease accumulation in the
supernatant and the impact of matrix degradation on
overall matrix accumulation would be trivial during such
a short period of incubation. If so, then 35S-incorporated-
ECM that accumulated during this period would repre-
Fig. 7. Effect of HGF on the net ECM accumulation by human proxi-sent newly synthesized and secreted ECM protein. The mal epithelial HKC cells. HKC cells were seeded on 12-well plates at
amount of matrix deposited by HKC cells and H4 cells a concentration of 5 3 105/well. Following a 24-hour incubation, the
media were changed to a serum-free, methionine-free medium supple-was virtually identical following 1.5 hours of incubation,
mented with 35S-labeled methionine. The net ECM accumulation wassuggesting that HGF does not decrease matrix synthesis. determined by counting the radioactivity of the ECM accumulated on
Similar results were obtained when HKC cells were incu- culture dishes during the indicated period of time. (A) The HKC cells
were incubated in the absence or presence of 20 ng/mL human recombi-bated without or with exogenous HGF (Fig. 9). These
nant HGF for 24 hours. (B) The HKC cells were incubated with eitherdata indicate that the reduction in ECM accumulation a specific anti-HGF neutralizing antibody (a-HGF; 1:200) or preimmune
by HGF is predominantly mediated by enhanced matrix serum in the presence of 20 ng/mL human recombinant HGF for 24
hours. It should be noted that because the experiments were carrieddegradation.
out in serum-free medium, the addition of either anti-HGF serum or
preimmune-serum at 1:200 (0.5%) enhanced ECM accumulation (B)HGF increases matrix metalloproteinase abundance compared with that without serum treatment (A). Data are expressed
as means 6 SE of six individual culture wells. *P , 0.05; **P , 0.01.Extracellular matrix degradation results primarily from
the action of a group of proteolytic enzymes known as
MMPs. We investigated the effect of HGF on MMP
protein abundance by immunoblotting using specific an- MMP-3 in HKC cells treated with or without exogenous
tibodies. HGF markedly increased MMP-9 abundance HGF by immunoblotting with specific monoclonal anti-
in human renal epithelial cells. MMP-9 protein was strik- bodies. The results revealed that the level of both MMP-2
ingly increased in the conditioned media of HKC cells and MMP-3 was extremely low or undetectable in HKC
treated with exogenous HGF as compared with the con- cells and that HGF did not significantly alter the expres-
trol (Fig. 10). Densitometry analysis revealed that the sion of these proteases in HKC cells (data not shown).
intensity of MMP-9 protein in conditioned media of
HGF decreases tissue inhibitors ofHKC cells treated with HGF was eightfold greater than
matrix metalloproteinasethat of control HKC cells.
To examine whether other MMPs are also regulated by Tissue inhibitors of MMPs are a family of specific
proteins that retard matrix degradation by blocking theHGF, we studied the protein abundance of MMP-2 and
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Fig. 8. Constitutive expression of HGF in
HKC cells reduces ECM accumulation and
deposition. An HGF-producing H4 cell line
was established by stable transfection of HKC
cells with an HGF-expression vector. Net ECM
accumulation was determined by counting the
radioactivity of the ECM deposited on culture
dishes after 24 hours of incubation, as de-
scribed in Figure 1. (A) Constitutive expres-
sion of HGF in the transfected H4 cells was
confirmed by Northern blot, showing a 2.3 kb
HGF mRNA expressed in H4 cells. (B) HGF
protein concentration in the supernatant mea-
sured by a specific ELISA. (C) Comparison of
the quantity of ECM accumulation by HKC
cells and HGF-producing H4 cells. (D) The
H4 cells were incubated with either a specific
anti-HGF neutralizing antibody (a-HGF; 1:200)
or preimmune serum for 24 hours. Data are
expressed as means 6 SE of six individual
culture wells. *P , 0.05; **P , 0.01.
proteolytic activity of MMPs [11]. To study the effects was performed using conditioned media from either re-
of HGF on TIMP levels, we quantitated TIMP-1 protein nal epithelial HKC cells or HGF-producing H4 cells.
by Western analysis in conditioned media from either This assay assesses the proteolytic activity of conditioned
HGF-producing H4 or wild-type HKC cells. TIMP-1 was media by determining its ability to break down collagen.
present in the media of HKC cells as a single 29 kD As shown in Figure 13, a marked increase in proteolytic
protein (Fig. 11A). Its abundance was significantly re- activity was observed in the conditioned media derived
duced in media derived from H4 cells, suggesting that from HGF-producing H4 cells, as compared with that
HGF suppresses TIMP-1 expression and secretion. To from control HKC cells. A prominent elevation in proteo-
confirm that HGF reduced TIMP-1 secretion by renal lytic activity was found in the positions corresponding to
epithelial cells, we also employed a specific ELISA to MMP-9 proteases, consistent with the result of immu-
measure the concentration of TIMP-1 that accumulated noblotting (Fig. 10). In contrast, the proteolytic activity
in conditioned media from HKC and H4 cells over 72 in the approximately 68 kD region, corresponding to
hours. This assay detected total TIMP-1 protein, which
MMP-2, was similar in wild-type and HGF-producing cellsincluded free TIMP-1 as well as TIMP-1 that is com-
(Fig. 13). These results demonstrate that HGF expressionplexed with MMPs. HGF expression significantly inhib-
in renal epithelial cells augments matrix degradation.ited TIMP-1 protein accumulation (Fig. 12). These data
indicate that HGF not only induces matrix degradation
enzymes such as MMP-9, but also suppresses production DISCUSSION
of the specific inhibitors of these enzymes.
Emerging evidence suggests that HGF not only pro-Similar results were obtained for TIMP-2 protein in
motes tissue repair and regeneration following acute in-renal epithelial cells. Western blotting revealed that
jury [26–28], but also modulates the development andHGF caused a significant reduction in the amount of
progression of chronic diseases that are characterized byTIMP-2 protein secreted into the conditioned media
progressive tissue fibrosis [6, 7, 29]. Consistent with this(Fig. 11B).
view, we found that activity of the endogenous renal
HGF activates matrix-degrading proteolytic cascade HGF/c-met axis was markedly increased in rats with
remnant kidneys (Fig. 1). Furthermore, blocking HGFTo investigate further whether HGF activates matrix-
degrading proteolytic pathways, zymographic analysis signaling with a specific neutralizing antibody acceler-
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Fig. 10. HGF stimulates MMP-9 expression in human renal epithelial
cells. Conditioned media were collected from HKC cells treated without
(control) and with 20 ng/mL recombinant human HGF for 48 hours in
serum-free medium. Similar quantities of conditioned media equalized
for protein were loaded on a nonreduced 10% SDS-polyacrylamide
gel. The proteins were immunoblotted with a specific human MMP-9
monoclonal antibody. The location of a 92 kD band corresponding to
MMP-9 is indicated.
These data provide further insight into the timing and
specificity of the HGF response in chronic renal disease.
A biphasic increase in HGF and c-met gene expression
was observed in remnant kidneys. An early peak that
coincided with the initial hyperplastic response to renal
mass reduction was followed by a later increase begin-
ning at two weeks after ablation, at a time when hyper-
tension and glomerular injury are first developing in this
model. This late increase in gene expression is sustained
out to at least eight weeks, the latest time point we have
examined. We also observed an increase in circulating
levels of HGF after ablation. This pattern of activation
with a systemic increase in HGF levels coupled with
Fig. 9. HGF does not affect the ECM synthesis rate in HKC cells. organ specific induction of c-met and biologic respon-
HKC cells and HGF-producing H4 cells were seeded on 12-well plates
siveness is similar to observations made in other injuryat a concentration of 5 3 105/well. The net ECM accumulation was
determined by counting the radioactivity of the ECM deposited on models, including toxic and ischemic acute renal failure
culture dishes following 1.5 hours of incubation. Since the impact of [21, 30] as well as acute injury in other organs [31, 32].
matrix degradation is minimal during this short period of time, ECM
The activation of endogenous HGF/c-met in chronicaccumulation is mainly determined by the rate of synthesis of new
ECM. (A) Comparison of quantity of newly synthesized ECM by HKC renal disease is beneficial, as the functional consequence
cells or by HGF-producing H4 cells. (B) Effect of HGF on ECM syn- of blocking HGF action was a rapid decline in GFR that
thesis in HKC cells. HKC cells were incubated either without (control)
was associated with a significant increase in morphologicor with 20 ng/mL human recombinant HGF for 1.5 hours (HGF). Data
are expressed as means 6 SE of six individual culture wells. abnormalities in both the glomeruli and interstitium of
remnant kidneys (Table 1 and Figs. 3 and 4). This rapid
onset of injury is remarkable given that GFR typically
remains constant for six to eight weeks and morphologic
ated the onset and progression of renal disease in these abnormalities progress slowly only reaching end stage
rats (Table 1 and Figs. 3 and 4), suggesting that the after several months in this model [13, 33]. In the kidney,
increase in HGF was beneficial in tending to preserve only a low level of expression of the HGF receptor,
kidney structure and function in this model. This obser- c-met, can be detected in the glomerulus [34], whereas
vation led us to examine the effects of HGF on ECM c-met is abundantly expressed by renal epithelial cells
turnover in kidney cells in vitro. We found that HGF along the entire nephron. These data suggest that the
significantly reduced net ECM accumulation by renal biologic target of HGF in chronic renal disease is the
epithelial HKC cells both acutely, after exposure of wild- renal tubular cell. As progressive renal fibrosis is a major
type cells to exogenous HGF, and chronically, in cells feature of this model, we examined the effects of HGF
made to constitutively express HGF by stable transfec- on matrix production and degradation by these cells.
tion. The HGF-induced reduction in ECM accumulation Extracellular matrix degradation is primarily mediated
appeared to be mediated primarily by an increase in by MMPs that together comprise a family of zinc-depen-
matrix degradation, and this, in turn, resulted from alter- dent proteases that can digest virtually all protein compo-
ations in several factors that regulate the activity of MMP nents of the ECM [9, 10, 35]. Based on their substrate
specificity, MMPs are grouped as collagenases, gela-family proteases.
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Fig. 12. HGF down-regulates TIMP-1 protein secretion in human renal
epithelial cells. Conditioned media were collected from HKC cells (h)
and HGF-producing H4 cells ( ) incubated in serum-free mediumFig. 11. HGF inhibits TIMP-1 and TIMP-2 expression in human renal
for different periods of time as indicated. Total TIMP-1 protein (freeepithelial cells. Conditioned media were collected from HKC cells and
TIMP-1 and TIMP-1/MMP binding complex) levels were quantitativelyHGF-producing H4 cells after incubation in serum-free medium for 48
measured using a specific ELISA for TIMP-1. Data are expressed ashours. Similar quantities of conditioned media equalized for protein
mean 6 SE of three individual culture plates. **P , 0.01 vs. controlwere loaded on a nonreduced 15% SDS-polyacrylamide gel at 15 mg
HKC cells.protein per lane. The proteins were immunoblotted with specific mono-
clonal antibodies against human TIMP-1 (A) and TIMP-2 (B), respec-
tively. The locations of the 29 kD TIMP-1 and 22 kD TIMP-2 bands
are indicated.
ever, TIMP expression increases concurrently in re-
sponse to these stimuli so that the net effect on ECM
catabolism is difficult to predict [5, 10, 11]. Generallytinases, and stromelysins. As expected for such potent
speaking, these cytokines are considered to be profibro-enzymes, MMP activity is tightly controlled in multiple
genic [2, 10, 11]. In contrast, HGF markedly stimulatesways, including: (1) their rate of synthesis and secretion,
MMP-9 expression while simultaneously down-regu-which is regulated at the transcriptional level; (2) their
lating TIMP production (discussed later in this article;post-translational conversion from latent zymogens to
Figs. 11 and 12). To date, this pattern of action onactive forms, which occurs in the extracellular space; and
ECM pathways is unique to HGF and identifies it as the(3) inhibition of the active enzymes via complexing with
only known cytokine with antifibrogenic activity demon-natural inhibitors called TIMPs [9–11]. Remarkably,
strated both in vitro and in vivo.HGF appears to alter MMP regulation at multiple levels
Proteolytic activity is partially regulated through thein a coordinated fashion tending to augment ECM re-
interaction of active MMPs with their natural inhibitors,moval. HGF induces MMP-9 expression and suppresses
the TIMPs. Thus far, four members of the TIMP familyexpression of the MMP inhibitors TIMP-1 and TIMP-2.
have been identified. All have common structural fea-These combined effects of HGF are predicted to result
tures and demonstrate approximately 30 to 50% identityin marked amplification of the matrix-degrading proteo-
in amino acid sequence [11]. TIMP-1 and TIMP-2 arelytic cascade (Fig. 13) and thereby have profound effects
capable of inhibiting the activities of all known MMPson the net accumulation and deposition of ECM by renal
and are believed to play a key role in maintaining theepithelial cells (Figs. 7 and 8).
balance between ECM deposition and degradation inAmong these actions, up-regulation of MMP-9 expres-
diverse settings. TIMP-1 is produced and secreted by asion by HGF may be the major mechanism leading to
variety of cell types and is widely distributed throughoutactivation of matrix-degrading proteolytic pathways in
the body, whereas TIMP-2 is produced in melanomarenal epithelial cells. HGF increased MMP-9 protein
cells, fibroblasts, macrophages, and renal proximal tu-abundance by eightfold in renal proximal tubular epithe-
bules [11, 39]. TIMP-3 is regulated in a cell cycle-depen-lial cells (Fig. 10). Of note, other cytokines, including
dent fashion in certain cell types and may serve as ainterleukin-1, tumor necrosis factor-a, platelet-derived
marker for terminal differentiation [40]. Recently clonedgrowth factor, and even transforming growth factor-b1
also stimulate MMP’s gene expression [5, 36–38]; how- in humans, TIMP-4 is highly expressed in the heart with
Liu et al: HGF ameliorates chronic renal injury 2041
cal changes that occur during embryonic development,
and proteolysis may be essential for cell migration and
growth during maturation. Consistent with an important
role for HGF in organogenesis, null-mutation of either
HGF or its c-met receptor in vivo results in a lethal
phenotype in mice [44–46]. Recent studies in vitro also
demonstrate that tubule formation by cultured renal epi-
thelial cells induced by exposure to conditioned media
rich in HGF is associated with increased MMP activity
[47]. Finally, the marked effect of HGF to stimulate
ECM degradation may also provide an explanation for
the permissive role that HGF plays in promoting detach-
Fig. 13. Zymographic analysis of the conditioned media derived from ment and migration of tumor cells and, thereby, the
HKC or HGF-producing H4 cells. Conditioned media were collected metastatic phenotype [48–50].from either HKC cells or HGF-producing H4 cells. Samples equalized
In summary, data in vitro and in vivo suggest that HGFfor protein content were separated on a 7.5% SDS-polyacrylamide
gel containing 0.1% gelatin. Proteolytic activity is demonstrated by is a potent antifibrogenic factor tending to reduce net ECM
digestion of gelatin, resulting in the bands of clearing. The numbers 1 accumulation by activating matrix degradation pathwaysthrough 6 in the picture identify media collected from separate culture
in renal tubular cells. HGF promotes matrix degradationplates. The band below MMP-2 is likely contributed by MMP-1. Similar
results were obtained when HKC cells were treated with or without by increasing MMP expression and by reducing the levels
recombinant human HGF (data not shown). of their specific inhibitors in a coordinated manner. En-
dogenous HGF levels rise, and renal c-met expression
is also induced in chronic renal disease; this tends to
preserve kidney structure and function. Whether admin-low or undetectable levels observed in other organs [41].
istration of additional exogenous HGF would furtherTIMPs inhibit MMP activity via reversible, noncovalent
retard renal scarring and progressive loss of kidney func-binding to the active forms of MMPs in a 1:1 molar ratio
tion in this model or in patients with chronic renal dis-[11]. Up-regulation of MMP expression concordant with
eases remains to be determined. Finally, because thedown-regulation of TIMPs expression by HGF in renal
HGF signaling system is present in many other organsepithelial cells would shift the balance of this interaction
including liver and lung, these findings may have broadto markedly favor matrix degradation.
implications for a wide range of “fibrogenic diseases.”It should be noted that in addition to directly activating
matrix degradation pathways, HGF may exert its potent
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